AUTHOR SUMMARY
Nuclear factor-erythroid2-related factor 2 (Nrf2) is a key transcription regulator of antioxidant and anti-inflammation enzymes. In the cytoplasm, Nrf2 binds to its endogenous inhibitor, Kelch-like ECH-associated protein 1 (Keap1). Various endogenous or environmental oxidative stresses, such as ionizing radiation (IR), can disrupt the Nrf2-Keap1 complex, which allows Nrf2 to translocate into the nucleus to induce transcription of heme oxygenase-1 (HO-1) and other cytoprotective enzymes by binding to genomic antioxidant responsive element (ARE) sequences (1) . Pharmacological concentrations of a synthetic triterpenoid activate Nrf2 and induce expression of HO-1, which can suppress IR-induced oxidative stress and inflammation (2) (Fig. P1 ). Increased Nrf2/ARE signaling by pretreatment with synthetic triterpenoids before irradiation is sufficient for protecting against oxidation-mediated DNA damage (3). However, the molecular mechanism by which Nrf2 functions in signaling induced by DNA double-strand breaks (DSBs) is unknown. Here, we provide robust evidence that Nrf2 protects cells from IR and induces DNA damage repair through direct binding to the 53BP1 promoter region harboring ARE sequences.
The synthetic triterpenoids, bardoxolone-methyl (BARD) or 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic acid (CDDO)-methyl ester and CDDO-ethyl amide (EA), belong to a distinct class of noncytotoxic, multifunctional, and orally available anti-inflammatory drugs that have been studied as inflammatory modulators and as anticancer agents in vitro and in vivo. When human colonic epithelial cells are treated with BARD before irradiation, BARD protects and increases the survival of cells. When cell are treated with BARD before irradiation, a significant reduction in residual IR-induced chromosomal aberrations was observed in metaphase cells. To determine if the effect of BARD on DNA DSB repair was due to changes in IR-induced signaling, we examined the appearance and disappearance of repairosomes, stable complexes of proteins that carry out DNA damage recognition and incision reactions characteristic of nucleotide excision repair. Consistent with the chromosome data, BARD treatment resulted in the rapid disappearance of repairosomes after irradiation. However, BARD failed to protect and increase repairosome formation in Nrf2-knockdown cell lines.
To explore the role of Nrf2 in the BARD-mediated DNA DSB repair activity, we examined the promoter regions of components of repairosomes, such as 53BP1, C-terminal binding protein interacting protein, and Rad51, to determine the presence of Nrf2-binding sites. Interestingly, the DNA repair protein 53BP1 promoter includes three ARE sequences to which Nrf2 binds directly, resulting in increased expression after BARD treatment (Fig. P1) . To investigate whether synthetic triterpenoids exert radioprotective activity in vivo, we fed mice with an EA derivative of a synthetic triterpenoid, CDDO-EA, which possesses enhanced pharmacodynamic activity in mouse assays compared with BARD (4). Oral treatment of CDDO-EA for 3 d before a lethal dose of total body irradiation (TBI) significantly improved the median survival of WT mice from 13 to 21.5 d. CDDO-EA preserved colonic crypt size, number, cell density, and villus length, which were observed 5 d after TBI.
To explore the effect of CDDO-EA on DNA damage signaling in vivo, we examined the appearance of 53BP1-positive cells in colonic crypts after TBI. Consistent with the cell experiments, CDDO-EA treatment resulted in the rapid appearance of 53BP1-positive cells and a shorter delay in DNA damage responses, suggesting that CDDO-EA also enhances the efficiency of DNA DSB repair in vivo. Collectively, these studies demonstrate that synthetic triterpenoids targeting Nrf2 are potent radioprotectors. The ease of administration and the relative lack of side effects support their further evaluation for clinical applications.
